Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[11] Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
Nilsson, Sten
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) : 1127 - 1136
[12] Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
Cha, Tai-Lung
Wu, Tony Tong-Lin
Vogelzang, Nicholas John
Huang, Chao-Yuan
Huang, Shu-Pin
Lin, Chia-Chi
Ou, Yen-Chuan
Pang, See-Tong
Shen, Daniel Heung-Yuan
Wu, Wen-Jeng
Chang, Wayne Yen-Hwa
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (11) : 825 - 836
[13] Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study
Huang, Chao-Yuan
Huang, Chi-Ping
Huang, Yu-Yi
Huang, Steven Kuan-Hua
Lu, Kevin
Huang, William Ji-Sien
Meng, En
Huang, Shu-Pin
Lee, Ming-Yang
Chen, Frank
Pang, See-Tong
INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (07) : 1268 - 1277
[14] Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
Prelaj, Arsela
Rebuzzi, Sara Elena
Buzzacchino, Federica
Pozzi, Chiara
Ferrara, Carla
Frantellizzi, Viviana
Follacchio, Giulia Anna
Civitelli, Liana
De Vincentis, Giuseppe
Tomao, Silverio
Bianco, Vincenzo
ONCOLOGY LETTERS, 2019, 17 (02) : 1467 - 1476
[15] Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
van der Zande, Kim
Oyen, Wim J. G.
Zwart, Wilbert
Bergman, Andries M.
CANCERS, 2021, 13 (17)
[16] Radium-223 for the treatment of castration-resistant prostate cancer
El-Amm, Joelle
Aragon-Ching, Jeanny B.
ONCOTARGETS AND THERAPY, 2015, 8 : 1103 - 1109
[17] Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity
Gomez-Veiga, F.
Alvarez-Ossorio, J. L.
Carballido-Rodriguez, J.
Juarez-Soto, A.
Rodriguez-Antolin, A.
Cozar-Olmo, J. M.
ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (10): : 616 - 624
[18] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Uemura, Hiroji
Uemura, Hirotsugu
Matsubara, Nobuaki
Kinuya, Seigo
Hosono, Makoto
Yajima, Yoko
Doi, Toshihiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 954 - 963
[19] Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
Anido-Herranz, Urbano
Fernandez-Calvo, Ovidio
Ruiz-Banobre, Juan
Martinez-Breijo, Sara
Fernandez-Nunez, Natalia
Nogareda-Seoane, Zulema
Garrido-Pumar, Miguel
Casas-Nebra, Javier
Muniz-Garcia, Gloria
Portela-Pereira, Paula
Gomez-Caamano, Antonio
Perez-Fentes, Daniel Adolfo
Santome-Couto, Lucia
Lazaro, Martin
Molina-Diaz, Aurea
Medina-Colmenero, Ana
Vazquez-Estevez, Sergio
FRONTIERS IN ONCOLOGY, 2024, 14
[20] Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer
Zhang, Isabella
Gilbo, Philip
Kohn, Nina
Cox, Brett
PRACTICAL RADIATION ONCOLOGY, 2018, 8 (06) : 452 - 457

← 1 2 3 4 5 →